Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma

J Allergy Clin Immunol. 2015 Sep;136(3):797-800. doi: 10.1016/j.jaci.2015.02.018. Epub 2015 Apr 2.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Anti-Asthmatic Agents / pharmacokinetics
  • Anti-Asthmatic Agents / therapeutic use*
  • Area Under Curve
  • Asthma / genetics
  • Asthma / metabolism
  • Asthma / pathology
  • Asthma / therapy*
  • DNA, Catalytic / pharmacokinetics
  • DNA, Catalytic / therapeutic use*
  • Drug Administration Schedule
  • Forced Expiratory Volume
  • GATA3 Transcription Factor / antagonists & inhibitors*
  • GATA3 Transcription Factor / genetics
  • GATA3 Transcription Factor / metabolism
  • Gene Expression
  • Humans
  • RNA, Messenger / antagonists & inhibitors*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Vital Capacity

Substances

  • Anti-Asthmatic Agents
  • DNA, Catalytic
  • GATA3 Transcription Factor
  • GATA3 protein, human
  • RNA, Messenger